GE Leads EU AI Cardio-Oncology Care Consortium
Chicago, USA – March 26, 2026 GE HealthCare announced a leading industrial role in the €50.5 million COMPASS consortium,...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Chicago, USA – March 26, 2026 GE HealthCare announced a leading industrial role in the €50.5 million COMPASS consortium,...
CHICAGO, ILLINOIS, March 23, 2026 GE HealthCare has announced that the U.S. Food and Drug Administration (FDA) has granted...
CHICAGO, Dec. 29, 2025 — GE HealthCare announced that its senior management team will present at an upcoming January...
